Marked activity of bortezomib, rituximab, and dexamethasone (BORID) in heavily pretreated patients with mantle cell lymphoma

Johannes Drach,H. Kaufmann,Oskar Pichelmayer,Verena Sagaster,Sonja Seidl,A Chott,Christoph C. Zielinski,Markus Raderer

Marked activity of bortezomib, rituximab, and dexamethasone (BORID) in heavily pretreated patients with mantle cell lymphoma

2006

Johannes Drach
H. Kaufmann
Oskar Pichelmayer
Verena Sagaster
Sonja Seidl
A Chott
Christoph C. Zielinski
Markus Raderer

17522 Background: Bortezomib (B) belongs to a new class of anti-cancer agents, the proteasome inhibitors, and has documented activity in multiple myeloma and mantle cell lymphoma (MCL). Preclinical...

Keywords:

Dexamethasone
Bortezomib/rituximab
Cancer research
Medicine
Mantle cell lymphoma
Pathology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations